Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 41 % of short-term debt in 2025; threshold 65 %.
-
Board fully replaced NBB
No director from three years ago is still active according to annual account 2025.
Financials
Financial year 2025
EUROPHARMACEUTICALS from Ukkel, company number BE0425594923, closed financial year 2025 with a result of € -19,213 after tax. For that financial year EUROPHARMACEUTICALS recorded a gross margin of € -15,369 and equity of € -2,911. Compared with financial year 2024, the result moved from € -15,668 to € -19,213. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.
€ -2,911
▼ € 19,213 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -19,213
▼ 23 % more loss than in 2024
Profit after tax over the fiscal year.
€ 22,171
▲ 10% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -64,911.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 67
▼ 69% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 543
▲ 185% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 8,671 | € 37,687 | € -3,265 | € -15,369 | ▼ € 12,104 |
| Profit after taxes | € -4,658 | € 25,308 | € -15,668 | € -19,213 | ▼ € 3,545 |
| Equity | € 6,662 | € 31,970 | € 16,302 | € -2,911 | ▼ € 19,213 |
| Total debts | € 67,635 | € 54,859 | € 50,317 | € 57,484 | ▲ 14% |
| Cash | € 9,454 | € 14,506 | € 20,103 | € 22,171 | ▲ 10% |
| Retained profit | € -55,338 | € -30,030 | € -45,698 | € -64,911 | ▼ € 19,213 |
| Bank debt | € 14,376 | € 2,055 | € 0 | € 0 | |
| Balance sheet total | € 74,296 | € 86,829 | € 66,619 | € 54,573 | ▼ 18% |
Key figures of EUROPHARMACEUTICALS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to EUROPHARMACEUTICALS?
What happened at EUROPHARMACEUTICALS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 19,213. Source: NBB ↗
- Marie-Laurence Geczy stepped down as director. NBB
- Marie-Laurence Geczy became a director. NBB
- New establishment in Ukkel. KBO
- Start of the company according to the CBE. KBO
In short
From € 4,658 loss in 2022 to € 19,213 loss in 2025.
Paid € 986 in corporate taxes since 2022.
Best year ever: 2023, with € 25,308 profit.
A new publication or filing at EUROPHARMACEUTICALS? We notify you, reason included.
Follow EUROPHARMACEUTICALSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind EUROPHARMACEUTICALS is Jozsef GECZY.
Directors
According to the 2025 annual accounts
Jozsef GECZY
Director
Marie-Laurence Geczy
Director
since 2006 · until 2025
Establishments
Establishment units
Physical locations of this company
Wolvendaellaan 21 box 6
1180 Ukkel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0425.594.923
- VAT number
- BE 0425.594.923
- Registered office
- Wolvendaellaan 21 bus 6, 1180 Ukkel
- Names & denominations
- EUROPHARMACEUTICALS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 March 1984
- Peppol
- Active · Active since 21 Aug 2025
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Vervaardiging van geneesmiddelen
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering